Integrating ghrelin assessments into broader biomarker panels, including 25-hydroxyvitamin D, adipokines, and inflammatory cytokines, could further support precision medicine strategies tailored to the metabolic and functional needs of individuals with DS. This evidence concerns the gene GHRL and Dravet syndrome.